Home » Stocks » TCON

TRACON Pharmaceuticals, Inc. (TCON)

Stock Price: $10.61 USD 0.47 (4.64%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $10.30 -0.31 (-2.92%) Jan 22, 7:03 PM
Market Cap 154.15M
Revenue (ttm) n/a
Net Income (ttm) -16.40M
Shares Out 10.51M
EPS (ttm) -2.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $10.61
Previous Close $10.14
Change ($) 0.47
Change (%) 4.64%
Day's Open 10.05
Day's Range 10.05 - 10.77
Day's Volume 310,582
52-Week Range 1.09 - 11.70

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 5 days ago

NDA was Submitted in November by TRACON's Corporate Partners, Alphamab Oncology and 3D Medicines, in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer NDA was Submit...

GlobeNewsWire - 2 weeks ago

SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targete...

GlobeNewsWire - 3 weeks ago

NDA was Submitted in November in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer NDA was Submitted in November in the Indication of MSI-H/dMMR Cancer, Including Co...

GlobeNewsWire - 3 weeks ago

SAN DIEGO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targete...

GlobeNewsWire - 1 month ago

SAN DIEGO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targete...

GlobeNewsWire - 1 month ago

Company Expects Interim Data in Mid-2021 Company Expects Interim Data in Mid-2021

Zacks Investment Research - 1 month ago

Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors.

Other stocks mentioned: ARPO, RGEN
GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...

GlobeNewsWire - 2 months ago

Submission for Approval Filed in Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer Submission for Approval Filed in Indication of MSI-H/dMMR Cancer, Including Colorectal...

Seeking Alpha - 2 months ago

TRACON Pharmaceuticals, Inc. (TCON) CEO Charles Theuer on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...

GlobeNewsWire - 2 months ago

SAN DIEGO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...

GlobeNewsWire - 2 months ago

SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...

GlobeNewsWire - 4 months ago

TRACON’s Pivotal ENVASARC Trial of envafolimab in the Sarcoma Subtypes of UPS and MFS Expected to Initiate Dosing in 4Q 2020 TRACON’s Pivotal ENVASARC Trial of envafolimab in the Sarcoma Subty...

GlobeNewsWire - 4 months ago

SAN DIEGO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targ...

GlobeNewsWire - 4 months ago

SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targ...

GlobeNewsWire - 4 months ago

SAN DIEGO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targe...

GlobeNewsWire - 4 months ago

SAN DIEGO, Aug. 27, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targe...

GlobeNewsWire - 5 months ago

Dosing in Pivotal Trial Expected to Begin in Fourth Quarter of 2020 in the U.S. Dosing in Pivotal Trial Expected to Begin in Fourth Quarter of 2020 in the U.S.

Seeking Alpha - 5 months ago

TRACON Pharmaceuticals' (TCON) CEO Charles Theuer on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targe...

GlobeNewsWire - 5 months ago

SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel target...

GlobeNewsWire - 6 months ago

Dosing in Pivotal Trial Expected to Begin in Second Half of 2020 at 25 Sites in the U.S. Dosing in Pivotal Trial Expected to Begin in Second Half of 2020 at 25 Sites in the U.S.

GlobeNewsWire - 6 months ago

Webinar to be held on Friday, July 17, at 11:00 AM Eastern Time Webinar to be held on Friday, July 17, at 11:00 AM Eastern Time

GlobeNewsWire - 7 months ago

SAN DIEGO, June 01, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targe...

GlobeNewsWire - 7 months ago

Undifferentiated Pleomorphic Sarcoma is the Major Sarcoma Subtype to be Enrolled in TRACON’s Pivotal ENVASARC Trial  of Envafolimab as a Single Agent and in Combination with Yervoy

Seeking Alpha - 8 months ago

TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targete...

GlobeNewsWire - 8 months ago

Company Reaches Agreement with Regulatory Agency on Key Elements  of ENVASARC Trial

GlobeNewsWire - 9 months ago

TRACON seeks licensing partner to develop and commercialize TRC253 in China TRACON seeks licensing partner to develop and commercialize TRC253 in China

GlobeNewsWire - 9 months ago

SAN DIEGO, April 14, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targe...

GlobeNewsWire - 10 months ago

SAN DIEGO, March 19, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targe...

GlobeNewsWire - 10 months ago

SAN DIEGO, March 16, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targe...

GlobeNewsWire - 10 months ago

OSAKA, Japan and SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; hereinafter, “Santen”) and TRACON Pharmaceuticals, Inc. (Head Office: San ...

Seeking Alpha - 10 months ago

TRACON Pharmaceuticals Inc. (TCON) CEO Charles Theuer on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 11 months ago

SAN DIEGO, Feb. 07, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel target...

Market Watch - 1 year ago

Shares of Tracon Pharmaceuticals Inc. TCON, -4.23% were up 29% in premarket trading on Friday after the company said it would partner with two Chinese companies to develop its investigational ...

GlobeNewsWire - 1 year ago

Company to Host Investor Conference Call Today at 8:30 a.m. ET / 5:30 a.m. PT

GlobeNewsWire - 1 year ago

SAN DIEGO, Nov. 08, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel target...

Seeking Alpha - 1 year ago

TRACON Pharmaceuticals' (TCON) CEO Charles Theuer on Q3 2019 Results - Earnings Call Transcript

GlobeNewsWire - 1 year ago

SAN DIEGO, Oct. 21, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel target...

GlobeNewsWire - 1 year ago

SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targe...

GlobeNewsWire - 1 year ago

SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel target...

GlobeNewsWire - 1 year ago

SAN DIEGO, Aug. 28, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel target...

Seeking Alpha - 1 year ago

TRACON Pharmaceuticals Inc. (TCON) CEO Charles Theuer on Q2 2019 Results - Earnings Call Transcript

Benzinga - 1 year ago

Shares of the thinly traded nanocap biotech TRACON Pharmaceuticals Inc (NASDAQ: TCON) were rallying Thursday.

Seeking Alpha - 1 year ago

TRACON Pharmaceuticals Inc. (TCON) CEO Charles Theuer on Q1 2019 Results - Earnings Call Transcript

Benzinga - 1 year ago

TRACON Pharmaceuticals Inc (NASDAQ: TCON), a thinly traded nanocap biotech, is plunging Friday after it announced shelving of a study of a pipeline asset.

Market Watch - 1 year ago

Tracon Pharmaceuticals Inc. shares slid 45% in premarket trade Friday, after the company said it is terminating a late-stage trial of a cancer treatment at the recommendation of an independent...

About TCON

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead clinical stage products include envafolimab (KN035), an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma. The company's clinical stage products also include DE-122, which is in randomized Phase IIa study for the treatment of wet AMD; TRC102, which is a small molecule that is in Phase II clinical trial for... [Read more...]

Industry
Biotechnology
IPO Date
Jan 30, 2015
CEO
Dr. Charles P. Theuer
Employees
19
Stock Exchange
NASDAQ
Ticker Symbol
TCON
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for TCON stock is "Buy." The 12-month stock price forecast is 9.17, which is a decrease of -13.57% from the latest price.

Price Target
$9.17
(-13.57% downside)
Analyst Consensus: Buy